While NRAS mutant cancers typically do not have NF1 or BRAF mutations, the G12D mutation likely still has some residual GTPase activity, explaining how NF1 loss and BRAF mutation provides a selective advantage for this branch of the melanoma evolution in patient 3. This evidence concerns the gene NRAS and cancer.